04.11.2014 • NewsLanxessMatthias Zachertlayoffs

Lanxess Realignment Could See 1,200 Jobs Go

A realignment scheme initiated by new Lanxess CEO Matthias Zachert last spring could see the chemical producer's 16,900-strong workforce cut by 7%, a German newspaper has reported.

The company has declined to comment before it publishes third-quarter results on Nov. 6.

Citing company sources, the daily Rheinische Post said it had learned that 1,200 jobs were on the chopping block as the world's largest synthetic rubber manufacturer deals with a global oversupply situation. It added that Lanxess plans to offer workers voluntary redundancy packages and early retirement schemes but also will not rule out layoffs.

As part of the company's three-phase Let's Lanxess Again strategy to take hold from January 2015, the CEO said earlier that it was likely to close production facilities in reaction to weak demand for auto ties and Asian competition.

Analysts have calculated that cutbacks in this dimension could save €50-60 million in costs annually.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.